iSAM Funds UK Ltd Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

iSAM Funds UK Ltd purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,869 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

Several other institutional investors have also bought and sold shares of CPRX. GAMMA Investing LLC raised its stake in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. Larson Financial Group LLC raised its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the period. CWM LLC lifted its holdings in Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Catalyst Pharmaceuticals during the second quarter worth about $70,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

CPRX has been the topic of a number of recent research reports. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Truist Financial increased their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $31.14.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $22.02 on Monday. The company has a market capitalization of $2.63 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.00 and a 52-week high of $24.27. The business’s fifty day moving average is $21.45 and its 200 day moving average is $18.98.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.